Provided by Tiger Fintech (Singapore) Pte. Ltd.

PagerDuty, Inc.

15.31
-0.0400-0.26%
Volume:27.34K
Turnover:416.98K
Market Cap:1.39B
PE:-25.86
High:15.32
Open:15.30
Low:15.07
Close:15.35
Loading ...

PagerDuty Declines 16% YTD: Should You Buy the Stock on the Dip?

Zacks
·
18 Dec 2024

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Business Wire
·
18 Dec 2024

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

PR Newswire
·
18 Dec 2024

Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics

GlobeNewswire
·
17 Dec 2024

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

GlobeNewswire
·
16 Dec 2024

PagerDuty (NYSE:PD investor three-year losses grow to 41% as the stock sheds US$116m this past week

Simply Wall St.
·
13 Dec 2024

JP Morgan downgrades PagerDuty and C3.ai on market dynamics

Investing.com
·
12 Dec 2024

PagerDuty Shares Down 2.1% After JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
11 Dec 2024

JPMorgan Downgrades PagerDuty to Underweight From Neutral, $21 Price Target

MT Newswires Live
·
11 Dec 2024

Not ‘If’ but ‘When’: 88% of Execs Expect a Major Incident in 2025 as Large as the July Global IT Outage

Business Wire
·
11 Dec 2024

Gain Therapeutics To Present At Biotech Showcase 2025

GlobeNewswire
·
11 Dec 2024

Why Cathie Wood May Have the Best Fund to Play Trump 2.0

Dow Jones
·
11 Dec 2024

PagerDuty (PD) was downgraded to a Sell Rating at J.P. Morgan

TIPRANKS
·
11 Dec 2024

PagerDuty Shares Down 3.3% Premarket After JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
11 Dec 2024

AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal

Zacks
·
10 Dec 2024

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Business Wire
·
10 Dec 2024

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

GlobeNewswire
·
09 Dec 2024

BRIEF-Pagerduty Appoints Sarah Franklin To Board Of Directors

Reuters
·
06 Dec 2024

PagerDuty Appoints Sarah Franklin to Board of Directors

THOMSON REUTERS
·
06 Dec 2024

PagerDuty Appoints Sarah Franklin to Board of Directors

Business Wire
·
06 Dec 2024